Author Suehisa, Hiroshi| Toyooka, Shinichi| Hotta, Katsuyuki| Uchida, Akiko| Soh, Junichi| Fujiwara, Yoshiro| Matsuo, Keitaro| Ouchida, Mamoru| Takata, Minoru| Kiura, Katsuyuki| Date, Hiroshi|
Published Date 2008-12-01
Publication Title 岡山医学会雑誌
Volume volume120
Issue issue3
Content Type Journal Article
FullText URL fulltext.pdf
Author Kano, Hirohisa| Ichihara, Eiki| Harada, Daijiro| Inoue, Koji| Kayatani, Hiroe| Hosokawa, Shinobu| Kishino, Daizo| Watanabe, Kazuhiko| Ochi, Nobuaki| Oda, Naohiro| Hara, Naofumi| Ninomiya, Kiichiro| Hotta, Katsuyuki| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords immune checkpoint inhibitor non-small cell-lung cancer PD-L1 pembrolizumab poor performance status
Published Date 2020-07-29
Publication Title Cancer Science
Volume volume111
Issue issue10
Publisher Wiley
Start Page 3739
End Page 3746
ISSN 1347-9032
NCID AA11808050
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2020 The Authors.
File Version publisher
PubMed ID 32726470
DOI 10.1111/cas.14590
Web of Science KeyUT 000562490200001
Related Url isVersionOf https://doi.org/10.1111/cas.14590
JaLCDOI 10.18926/AMO/60802
FullText URL 74_5_423.pdf
Author Hirabae, Atsuko| Ichihara, Eiki| Sunami, Ryota| Ota, Moeko| Iwamoto, Yoshitaka| Maeda, Yoshinobu| Kiura, Katsuyuki|
Abstract We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks.
Keywords lung cancer immune checkpoint inhibitors pembrolizumab hyperprogression
Amo Type Case Report
Published Date 2020-10
Publication Title Acta Medica Okayama
Volume volume74
Issue issue5
Publisher Okayama University Medical School
Start Page 423
End Page 425
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2020 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 33106698
JaLCDOI 10.18926/AMO/55446
FullText URL 71_5_453.pdf
Author Taniguchi, Akihiko| Miyahara, Nobuaki| Oda, Naohiro| Morichika, Daisuke| Ichihara, Eiki| Oze, Isao| Tanimoto, Yasushi| Ichikawa, Hirohisa| Fujii, Utako| Tanimoto, Mitsune| Kanehiro, Arihiko| Kiura, Katsuyuki|
Abstract Although recent retrospective studies suggested that the use of β-blockers appears to help improve the mortality rate and decrease the rate of exacerbation in chronic obstructive pulmonary disease (COPD) patients with heart failure, the effects of β-blockers on COPD patients without heart failure have not been established. Based on previous reports, we have launched a multicenter, prospective, single-arm phase II study to evaluate the preventive effect of the cardioselective β-blocker bisoprolol in COPD exacerbation, in Japanese individuals with moderate-to-severe COPD who do not have heart failure but do have hypertension requiring the use of medication. The primary endpoint is the rate of mild-to-severe COPD exacerbation. The results of this study will clarify whether bisoprolol can prevent exacerbation in COPD patients without heart failure.
Keywords chronic obstructive pulmonary disease β-blocker bisoprolol exacerbation heart failure
Amo Type Clinical Study Protocol
Published Date 2017-10
Publication Title Acta Medica Okayama
Volume volume71
Issue issue5
Publisher Okayama University Medical School
Start Page 453
End Page 457
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2017 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 29042706
Author Higo, Hisao| Miyahara, Nobuaki| Taniguchi, Akihiko| Senoo, Satoru| Itano, Junko| Watanabe, Hiromi| Oda, Naohiro| Kayatani, Hiroe| Ichikawa, Hirohisa| Shibayama, Takuo| Kajimoto, Kazuhiro| Tanimoto, Yasushi| Kanehiro, Arihiko| Maeda, Yoshinobu| Kiura, Katsuyuki| OKAYAMA respiratory disease study group (ORDSG)|
Keywords Idiopathic pulmonary fibrosis High-resolution computed tomography Pirfenidone Forced vital capacity
Note This fulltext is available in Feb. 2021.|
Published Date 2020-02-23
Publication Title Respiratory Investigation
Volume volume58
Issue issue3
Publisher Elsevier
Start Page 185
End Page 189
ISSN 22125345
NCID AA12579673
Content Type Journal Article
language 英語
File Version author
PubMed ID 32102769
DOI 10.1016/j.resinv.2019.12.007
Web of Science KeyUT 000531841500009
Related Url isVersionOf https://doi.org/10.1016/j.resinv.2019.12.007
FullText URL fulltext.pdf
Author Senoo, Satoru| Miyahara, Nobuaki| Taniguchi, Akihiko| Oda, Naohiro| Itano, Junko| Higo, Hisao| Hara, Naofumi| Watanabe, Hiromi| Kano, Hirohisa| Suwaki, Toshimitsu| Fuchimoto, Yasuko| Kajimoto, Kazuhiro| Ichikawa, Hirohisa| Kudo, Kenichiro| Shibayama, Takuo| Tanimoto, Yasushi| Kuyama, Shoichi| Kanehiro, Arihiko| Maeda, Yoshinobu| Kiura, Katsuyuki| Okayama Respiratory Disease Study Group (ORDSG)|
Published Date 2020-08-27
Publication Title PLoS ONE
Volume volume15
Issue issue8
Publisher Public Library of Science
Start Page e0236935
ISSN 1932-6203
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2020 Senoo et al.
File Version publisher
PubMed ID 32853277
DOI 10.1371/journal.pone.0236935
Web of Science KeyUT 000566948800009
Related Url isVersionOf https://doi.org/10.1371/journal.pone.0236935
Author Shien, Kazuhiko| Toyooka, Shinichi| Ichimura, Kouichi| Soh, Junichi| Furukawa, Masashi| Maki, Yuho| Muraoka, Takayuki| Tanaka, Norimitsu| Ueno, Tsuyoshi| Asano, Hiroaki| Tsukuda, Kazunori| Yamane, Masaomi| Oto, Takahiro| Kiura, Katsuyuki| Miyoshi, Shinichiro|
Published Date 2012-07
Publication Title Lung Cancer
Volume volume77
Issue issue1
Content Type Journal Article
Author Ueno, Tsuyoshi| Tsukuda, Kazunori| Toyooka, Shinichi| Ando, Midori| Takaoka, Munenori| Soh, Junichi| Asano, Hiroaki| Maki, Yuho| Muraoka, Takayuki| Tanaka, Norimitsu| Shien, Kazuhiko| Furukawa, Masashi| Yamatsuji, Tomoki| Kiura, Katsuyuki| Naomoto, Yoshio| Miyoshi, Shinichiro|
Published Date 2012-04
Publication Title Lung Cancer
Volume volume76
Issue issue1
Content Type Journal Article
JaLCDOI 10.18926/AMO/54514
FullText URL 70_4_327.pdf
Author Watanabe, Mototsugu| Yamamoto, Hiromasa| Eikawa, Shingo| Shien, Kazuhiko| Shien, Tadahiko| Soh, Junichi| Hotta, Katsuyuki| Wada, Jun| Hinotsu, Shiro| Fujiwara, Toshiyoshi| Kiura, Katsuyuki| Doihara, Hiroyoshi| Miyoshi, Shinichiro| Udono, Heiichiro| Toyooka, Shinichi|
Abstract A study to evaluate the effect of metformin on the immune system was commenced in July 2014. Metformin is one of the most commonly prescribed drugs for type 2 diabetes, and previous studies have reported that metformin has an anti-tumor effect. The aim of this study is to evaluate the efficacy of metformin on the immune system in human cancer patients in vivo. The primary outcome parameter will be the rate change in the population of CD8+ T cells, which produce multiple cytokines.
Keywords metformin CD8+ T cells cancer immunology
Amo Type Clinical Study Protocols
Published Date 2016-08
Publication Title Acta Medica Okayama
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 327
End Page 330
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549683
Web of Science KeyUT 000384748600018
Author Murakami, Toshi| Takigawa, Nagio| Ninomiya, Takashi| Ochi, Nobuaki| Yasugi, Masaaki| Honda, Yoshihiro| Kubo, Toshio| Ichihara, Eiki| Hotta, Katsuyuki| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2014-01
Publication Title Lung Cancer
Volume volume83
Issue issue1
Content Type Journal Article
Title Alternative Treatment for a non-compliant patient with cancer and epilepsy
FullText URL 126_133.pdf
Author Minami, Daisuke| Ichihara, Eiki| Okabe, Nobuyuki| Yokomichi, Naosuke| Kouge, Noriko| Kajizono, Makoto| Akimoto, Yutaka| Hori, Keisuke| Matsubara, Minoru| Nasu, Junichiro| Tanimoto, Mitsune| Kiura, Katsuyuki| Matsuoka, Junzi|
Abstract  A 58-year-old man with cervical esophageal cancer and a history of epilepsy was treated with chemoradiotherapy from May of 2013. When tube feeding was initiated due to aspiration pneumonitis, the patient showed a degree of irritability that affected routine staff work and treatment compliance. We attempted to perform supportive care for maladjustment by the notice, the fast, and the tube feeding, but there was no improvement. After we added carbamazepine, primidone, and propericiazine (which had been canceled at the initiation of the tube feeding) to the patient's intravenous phenytoin, the symptoms and treatment compliance improved significantly. We concluded that the causes of the patient's irritability were maladjustment and his epilepsy.
Keywords てんかん(epilepsy) 易怒性(irritability) 適応障害(maladjustment)
Publication Title 岡山医学会雑誌
Published Date 2014-08-01
Volume volume126
Issue issue2
Start Page 133
End Page 135
ISSN 0030-1558
language 日本語
Copyright Holders Copyright (c) 2014 岡山医学会
File Version publisher
DOI 10.4044/joma.126.133
NAID 130004685264
Author Yasugi, Masayuki| Takigawa, Nagio| Ochi, Nobuaki| Ohashi, Kadoaki| Harada, Daijiro| Ninomiya, Takashi| Murakami, Toshi| Honda, Yoshihiro| Ichihara, Eiki| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2014-08-15
Publication Title Experimental Cell Research
Volume volume326
Issue issue2
Content Type Journal Article
JaLCDOI 10.18926/AMO/54499
FullText URL 70_4_243.pdf
Author Osawa, Masahiro| Ohashi, Kadoaki| Kubo, Toshio| Ichihara, Eiki| Takata, Saburo| Takigawa, Nagio| Takata , Minoru| Tanimoto, Mitsune| Kiura, Katsuyuki|
Abstract Vandetanib (ZactimaTM) is a novel, orally available inhibitor of both vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase. In the present study, a line of transgenic mice with a mouse Egfr gene mutation (delE748-A752) corresponding to a human EGFR mutation (delE746-A750) was established. The transgenic mice developed atypical adenomatous hyperplasia to adenocarcinoma of the lung at around 5 weeks of age and died of lung tumors at approximately 17 weeks of age. In the mice treated with vandetanib (6mg/kg/day), these lung tumors disappeared and the phosphorylations of EGFR and VEGFR-2 were reduced in lung tissues to levels comparable to those of non-transgenic control mice. The median overall survival time of the transgenic mice was 28 weeks in the vandetanib-treated group and 17 weeks in the vehicle-treated group. Vandetanib significantly prolonged the survival of the transgenic mice (log-rank test, p<0.01); resistance to vandetanib occurred at 20 weeks of age and the animals died from their lung tumors at about 28 weeks of age. These data suggest that vandetanib could suppress the progression of tumors harboring an activating EGFR mutation.
Keywords vandetanib VEGFR EGFR nonsmall cell lung cancer transgenic mouse
Amo Type Original Article
Published Date 2016-08
Publication Title Acta Medica Okayama
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 243
End Page 253
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549668
Web of Science KeyUT 000384748600003
FullText URL J_Thorac_Oncol_201907017.pdf
Author Makimoto, Go| Ohashi, Kadoaki| Tomida, Shuta| Nishii, Kazuya| Matsubara, Takehiro| Kayatani, Hiroe| Higo, Hisao| Ninomiya, Kiichiro| Sato, Akiko| Watanabe, Hiromi| Kano, Hirohisa| Ninomiya, Takashi| Kubo, Toshio| Rai, Kammei| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Toyooka, Shinichi| Takata, Minoru| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords ALK G1202R Alectinib Amphiregulin MET NSCLC
Published Date 2019-07-30
Publication Title Journal of Thoracic Oncology
Volume volume14
Issue issue11
Publisher Elsevier
Start Page 2009
End Page 2018
ISSN 15560864
NCID AA12058455
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
File Version author
PubMed ID 31374369
DOI 10.1016/j.jtho.2019.07.017
Web of Science KeyUT 000492678300025
Related Url isVersionOf https://doi.org/10.1016/j.jtho.2019.07.017
FullText URL fulltext.pdf
Author Itano, Junko| Ohashi, Kadoaki| Senoo, Satoru| Oda, Naohiro| Nishii, Kazuya| Taniguchi, Akihiko| Miyahara, Nobuaki| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords Axillary lymphadenitis Mycobacterium avium complex infection Mycobacterium intracellulare
Published Date 2019
Publication Title Respiratory Medicine Case Reports
Volume volume28
Publisher Elsevier
Start Page 100947
ISSN 2213-0071
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2019 The Authors.
File Version publisher
PubMed ID 31681532
DOI 10.1016/j.rmcr.2019.100947
Web of Science KeyUT 000511444900001
Related Url isVersionOf https://doi.org/10.1016/j.rmcr.2019.100947
FullText URL fulltext.pdf
Author Makimoto, Go| Ohashi, Kadoaki| Taniguchi, Kohei| Soh, Junichi| Taniguchi, Akihiko| Miyahara, Nobuaki| Toyooka, Shinichi| Yoshino, Tadashi| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords IgG4-related disease Pleural effusion Adenosine deaminase Pleural biopsy Spontaneous remission
Published Date 2019
Publication Title Respiratory Medicine Case Reports
Volume volume28
Publisher Elsevier
Start Page 100938
ISSN 2213-0071
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2019 The Authors.
File Version publisher
PubMed ID 31667074
DOI 10.1016/j.rmcr.2019.100938
Web of Science KeyUT 000511444900052
Related Url isVersionOf https://doi.org/10.1016/j.rmcr.2019.100938
FullText URL fulltext.pdf figs.pdf tables.pdf
Author Itano, Junko| Higo, Hisao| Ohashi, Kadoaki| Makimoto, Go| Nishii, Kazuya| Hotta, Katsuyuki| Miyahara, Nobuaki| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords osimertinib drug-induced ILD reversed halo sign organizing pneumonia pattern re-administration
Published Date 2020-03-15
Publication Title Internal Medicine
Volume volume59
Issue issue6
Publisher The Japanese Society of Internal Medicine
Start Page 823
End Page 828
ISSN 0918-2918
NCID AA10827774
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2020 by The Japanese Society of Internal Medicine
File Version author
PubMed ID 31787696
DOI 10.2169/internalmedicine.3689-19
Web of Science KeyUT 000521137500011
Related Url isVersionOf https://doi.org/10.2169/internalmedicine.3689-19
JaLCDOI 10.18926/AMO/60796
FullText URL 74_5_371.pdf
Author Makimoto, Go| Ohashi, Kadoaki| Maeda, Yoshinobu| Kiura, Katsuyuki|
Abstract The prognosis of advanced non-small cell lung cancer (NSCLC) patients has improved in recent decades, especially for patients with an oncogenic driver mutation. Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are effective for patients with the echinoderm microtubule-associated protein-like 4-ALK fusion gene. Several ALK-TKIs have been established: the first-generation ALK-TKI, crizotinib; second-generation ALK-TKIs, alectinib and ceritinib; and third-generation ALK-TKI, lorlatinib. Some ALK-TKIs are effective for tumors that are resistant to other ALK-TKIs; however, as is known in epidermal growth factor receptormutant lung cancer, tumor resistance is inevitable. ALK-positive NSCLCs acquire resistance via various mechanisms, making it a heterogeneous disease. Therefore, it is necessary to develop next-generation treatment strategies, such as the use of next-generation ALK-TKIs for secondary mutations, or combination therapies with ALK-TKIs and other TKIs. In this review, we summarize the development and use of ALK-TKIs, prior pivotal clinical trials, and resistance mechanisms.
Keywords lung cancer anaplastic lymphoma kinase tyrosine kinase inhibitors resistance mechanism
Amo Type Review
Published Date 2020-10
Publication Title Acta Medica Okayama
Volume volume74
Issue issue5
Publisher Okayama University Medical School
Start Page 371
End Page 379
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2020 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 33106692
Title Alternative A prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations (the HER2-CS Study) and a phase II study of trastuzumab emtansine (recombinant) in patients with HER2-positive non-small cell lung cancer who recurred, progressed after standard chemotherapy, or were primarily refractory to standard chemotherapy
FullText URL 127_127.pdf
Author Kiura, Katsuyuki| Hotta, Katsuyuki| Sato, Akiko| Ohashi, Kadoaki| Ninomiya, Takashi| Minnami, Daisuke| Tabata, Masahiro| Kubo, Toshio| Kato, Yuka| Hirata, Taizo|
Keywords 臨床研究中核病院 国立研究開発法人日本医療研究開発機構 文部科学省橋渡し研究加速ネットワークプログラム HER2-CS study trastuzumab emtansine
Publication Title 岡山医学会雑誌
Published Date 2015-08-03
Volume volume127
Issue issue2
Start Page 127
End Page 132
ISSN 0030-1558
Related Url isVersionOf https://doi.org/10.4044/joma.127.127
language 日本語
Copyright Holders Copyright (c) 2015 岡山医学会
File Version publisher
DOI 10.4044/joma.127.127
NAID 130005096256
Author Taniguchi, Akihiko| Miyahara, Nobuaki| Nakahara, Atsushi| Takata, Saburo| Sakugawa, Ryo| Nagano, Osamu| Tanimoto, Yasushi| Kanehiro, Arihiko| Kiura, Katsuyuki| Ujike, Yoshito| Tanimoto, Mitsune|
Published Date 2011-12-01
Publication Title 岡山医学会雑誌
Volume volume123
Issue issue3
Content Type Journal Article